Common TitleATLAS
Official Title A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current INI- NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-infected Adults Who Are Virologically Suppressed
Phase Phase III
ClinicalTrials.gov NCT02951052
Treatments
Injectable cabotegravir and Rilpivirine
Injectable cabotegravir and Rilpivirine
Tradename:CabenuvaClass:Long-Acting Injectable RegimensCategories Treatment-ExperiencedDual Therapy
Funding
IndustryViiV Healthcare and Janssen
References
- Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. N Engl J Med. 2020;382:1112-23.